SABCS 2023盛幕将启,中国之声汇总!(3)

作者:肿瘤瞭望   日期:2023/12/4 13:53:18  浏览量:1185

肿瘤瞭望版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

第46届圣安东尼奥乳腺癌研讨会(SABCS)将于当地时间2023年12月5日至9日在美国得克萨斯州圣安东尼奥举行,SABCS作为乳腺癌领域规模最大,最具影响力的国际性会议,届时多项重磅研究结果将在会上公布。《肿瘤瞭望》现将中国专家投稿摘要号及题目进行汇总(Poster Sessions部分排名不分先后),如有遗漏或错误,欢迎广大读者后台留言。

编者按:第46届圣安东尼奥乳腺癌研讨会(SABCS)将于当地时间2023年12月5日至9日在美国得克萨斯州圣安东尼奥举行,SABCS作为乳腺癌领域规模最大,最具影响力的国际性会议,届时多项重磅研究结果将在会上公布。《肿瘤瞭望》现将中国专家投稿摘要号及题目进行汇总(Poster Sessions部分排名不分先后),如有遗漏或错误,欢迎广大读者后台留言。
 
Poster Sessions
 
专场:POSTER SESSION 3
时间:12月7日12:00 pm-2:00 pm
地点:Halls 2-3
 
PO3-01-01 Dysregulation of Phenylalanine-tyrosine Metabolic Signaling Pathway and Neoadjuvant Response in HER2-positive Breast Cancer
HER2阳性乳腺癌中苯丙氨酸-酪氨酸代谢信号通路失调和新辅助反应
第一作者:Chih Wan Goh(复旦大学附属肿瘤医院)
 
PO3-02-08 Risk factors and a new predictive nomogram for predicting the Non-sentinel Lymph Node Metastasis in 708 early-stage Breast Cancer Patients with Positive Sentinel Nodes in China
708例中国早期乳腺癌前哨淋巴结阳性患者的危险因素及非前哨淋巴结转移的新预测图
第一作者:宋振川(河北医科大学第四医院)
 
PO3-02-12 Dalpiciclib combination with letrozole as neoadjuvant therapy for HR-positive HER2-negative breast cancer:a single-arm,prospective exploratory clinical study
达尔西利联合来曲唑作为HR阳性/HER2阴性乳腺癌的新辅助治疗:一项单臂前瞻性探索性临床研究
第一作者:Jingruo Li(郑州大学第一附属医院)
 
PO3-04-05 Efficacy and safety of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive or HER2-low expressing,metastatic breast cancer:a single-arm phase II study
重组人源化抗her2单克隆抗体-MMAE偶联RC48-ADC在HER2阳性或HER2低表达转移性乳腺癌患者中的疗效和安全性:一项单臂Ⅱ期研究
第一作者:Fei Qu(南京医科大学第一附属)
 
PO3-04-09 Prognoses of Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy before Surgery:A Retrospective Analysis
HR+/HER2-乳腺癌患者术前接受新辅助化疗的预后:回顾性分析
第一作者:张瑾(天津医科大学肿瘤医院)
 
PO3-05-10 Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer(MBC):A multi-center,open-label,single-arm,phase II study
艾立布林联合吉西他滨在HER2-转移性乳腺癌患者二线或二线以上的疗效和安全性:一项多中心、开放标签、单臂、Ⅱ期研究
第一作者:PeiJian Peng(中山大学附属第五医院)
 
PO3-06-06 Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer(CHANGEABLE):an open-label,single-arm,phase II study
HX008和尼拉帕利联合治疗胚系突变转移性乳腺癌(CHANGEABLE):一项开放标签、单臂、Ⅱ期研究
第一作者:张剑(复旦大学附属肿瘤医院)
 
PO3-06-07 Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple negative breast cancer(SPACE):preliminary results of a single-arm,multicenter phase II trial
sintilmab联合anlotinib节拍化疗治疗晚期三阴性乳腺癌的疗效和安全性(SPACE):单臂,多中心Ⅱ期试验的初步结果
第一作者:李慧慧(山东省肿瘤医院)
 
PO3-06-11 Undated analyses from a Phase Ib open-label study of Pucotenlimab(HX008)in combination with gemcitabine and cisplatin as first-line treatment of metastatic triple-negative breast cancer
Pucotenlimab(HX008)联合吉西他滨和顺铂作为转移性三阴性乳腺癌一线治疗的Ib期开放标签研究的最终分析
第一作者:胡夕春(复旦大学附属肿瘤医院)
 
PO3-08-09 Unique molecular signatures of germline mutations in low expression of human epidermal growth factor receptor 2(HER2)breast cancer
人表皮生长因子受体2(HER2)低表达乳腺癌胚系突变的独特分子特征
第一作者:廖宁(广东省人民医院)
 
PO3-08-10 Somatic mutations of a multigene panel in Chinese HER2-positive patients undergoing neoadjuvant therapy and impact on prognosis based on TP53 status:a single-institution retrospective cohort
在接受新辅助治疗的中国HER2阳性乳腺癌患者中,多基因组的体细胞突变及其对基于TP53状态的预后影响:一项单机构回顾性队列研究
第一作者:Min Xiong(复旦大学附属肿瘤医院)
 
PO3-11-09 Cross-cultural adaptation and psychometric validation of lymphedema patient-reported outcome measurements in Chinese breast cancer patients
中国乳腺癌患者淋巴水肿患者报告结果测量的跨文化适应和心理测量验证
第一作者:Yue Zhou(复旦大学附属肿瘤医院)
 
PO3-14-01 Heterogeneity of tumor immune microenvironment to predict everolimus efficacy in premenopausal women with hormone receptor-positive/human epidermal growth factor receptor 2-negative adavanced breast cancer
肿瘤免疫微环境的异质性预测依维莫司在HR+/HER2-绝经前晚期乳腺癌患者中的疗效
第一作者:Yujing Tan(中国医学科学院肿瘤医院)
 
PO3-14-05 Integration of metabolomics and transcriptomics to Reveal Potential Biomarkers Associated with Treatment Response of Neoadjuvant Therapy in HER2+Breast Cancer
整合代谢组学和转录组学揭示与HER2+乳腺癌新辅助治疗反应相关的潜在生物标志物
第一作者:Ningning Zhang(重庆大学附属肿瘤医院)
 
PO3-15-01 Overexpression of N-glycosylation related gene OST4 promotes chemotherapy resistance in triple-negative breast cancer.
n-糖基化相关基因OST4过表达促进三阴性乳腺癌化疗耐药
第一作者:Wei Wang(上海市第一人民医院)
 
PO3-15-06 Identification of a Novel Five Ferroptosis-Related Gene Signature as a Promising Prognostic Model for Breast Cancer
鉴定一种新的五种凋亡相关基因标记作为乳腺癌的预后模型
第一作者:Tian-cheng Cheng(常州市第二人民医院)
 
PO3-18-03 Preoperative single-dose camrelizumab and/or microwave ablation in women with earlystage breast cancer:A randomized window-of-opportunity trial
术前单次剂量卡瑞利珠单抗和/或微波消融治疗早期乳腺癌女性患者:一项随机、机会窗试验
第一作者:周文斌(南京医科大学第一附属医院)
 
PO3-22-09 Implementation of nanoparticle-assisted axillary staging:reduced axillary intervention for patients with node-positive breast cancer following neoadjuvant therapy
纳米粒子辅助腋窝分期:减少淋巴结阳性乳腺癌患者在新辅助治疗后的腋窝干预
第一作者:Ruixian Chen(四川大学华西医院)
 
PO3-23-04 Patient-reported outcomes and complication profiles of implant-based breast reconstruction in patients with postmastectomy radiation therapy
患者报告的乳房切除术后放疗患者植入式乳房重建的结果和并发症概况
第一作者:Jian Liu(杭州市第一人民医院)
 
PO3-24-03 Cisplatin synergizes immune checkpoint blocking through RNFT1 mediated PD-L1 recycling in Triple Negative Breast Cancer
在三阴性乳腺癌中,顺铂通过RNFT1介导的PD-L1循环协同免疫检查点阻断
第一作者:Jiahui Chu(南京医科大学)
 
PO3-24-04 Altered epigenetic modifications and genome architecture reshape lipid metabolism during secondary trastuzumab resistance formation of HER2-positive breast cancer
在HER2阳性乳腺癌继发性曲妥珠单抗耐药形成过程中,表观遗传修饰和基因组结构改变重塑了脂质代谢
第一作者:Ningjun Duan(南京医科大学第一附属医院)
 
PO3-24-05 Cysteine metabolism related ferroptosis sensitivity in trastuzumab resistant HER2 positive breast cancer
曲妥珠单抗耐药HER2阳性乳腺癌中半胱氨酸代谢相关的铁下垂敏感性
第一作者:殷咏梅(南京医科大学第一附属医院)
 
PO3-24-10 Losartan enhances the radiosensitivity of triple-negative breast cancer by reshaping the tumor immune microenvironment
氯沙坦通过重塑肿瘤免疫微环境增强三阴性乳腺癌的放射敏感性
第一作者:Cuiwei Liu(华中科技大学同济医学院附属协和医院)
 
PO3-25-12 Tigecycline-Induced Metabolic Reprogramming and Cytokine Modulation Suppress the Characteristics of Breast Cancer Cells
替加环素诱导的代谢重编程和细胞因子调节抑制乳腺癌细胞的特征
第一作者:Haochen Yu(重庆医科大学附属第一医院)
 
PO3-27-12 Dexamethasone is necessary for preventing acute emesis induced by anthracycline/cyclophosphamide chemotherapy(HELEN-009):a multicenter,randomized,openlabeled phase 3 trial
地塞米松对于预防蒽环类药物/环磷酰胺化疗引起的急性呕吐是必要的(HELEN-009):一项多中心、随机、开放标记的3期试验
第一作者:Xiuchun Chen(河南省肿瘤医院)
 
PO3-28-04 Ganglioside-Monosialic Acid for Prevention of Peripheral Neuropathy Induced by nab-Paclitaxel in Breast Cancer Patients(HELEN-004):A Randomized,Double-Blind,Phase II Trial
神经节苷-单唾液酸预防乳腺癌患者nab-紫杉醇引起的周围神经病变(HELEN-004):一项随机、双盲、Ⅱ期试验
第一作者:Zhenduo Lu(河南省肿瘤医院)
 
专场:POSTER SESSION 4
时间:12月7日5:00 pm-7:00 pm
地点:Halls 2-3
 
PO4-01-13 Effect of interruption or discontinuation of endocrine therapy on the prognosis of breast cancer patients:a cohort study using the real-world database
中断或停止内分泌治疗对乳腺癌患者预后的影响:一项使用真实世界数据库的队列研究
第一作者:Ya Huang(四川大学华西医院)
 
PO4-03-13 High B7-H3 expression with low PD-L1 expression identifies armored-cold tumors suggesting potential anti-B7-H3 therapy in triple-negative breast cancer
B7-H3高表达和PD-L1低表达可识别冷肿瘤,提示抗B7-H3治疗可能用于三阴性乳腺癌
第一作者:Jie Mei(南京医科大学第一附属医院)
 
PO4-04-02 Real-world first line use of trastuzumab biosimilar(HLX02),pertuzumab and chemotherapy for Chinese patients with HER2-positive metastatic breast cancer
中国HER2阳性转移性乳腺癌患者在真实世界中一线使用曲妥珠单抗生物仿制药(HLX02)+帕妥珠单抗+化疗的疗效
第一作者:Ruyan Zhang(北京大学肿瘤医院)
 
PO4-04-04 A Multicenter,Retrospective,Real World Study of Inetetamab Combined with Pyrotinib and Vinorelbine as Treatment for HER2-positive Metastatic Breast Cancer
一项多中心、回顾性、真实世界的研究:伊尼妥单抗+吡咯替尼+长春瑞滨治疗HER2阳性转移性乳腺癌
第一作者:殷咏梅(南京医科大学第一附属医院)
 
PO4-04-06 Exploring the use of tyrosine kinase inhibitors(TKIs)in the management of HER2-positive metastatic breast cancer post trastuzumab emtansine(T-DM1)therapy failure:Insights from a realworld study
探索酪氨酸激酶抑制剂(TKIs)在T-DM1治疗失败后的HER2阳性转移性乳腺癌管理中的应用:来自真实世界研究的观点
第一作者:殷咏梅(南京医科大学第一附属医院)
 
PO4-04-07 Efficacy,safety and translational study of pyrotinib combined with albumin-bound paclitaxel as firstline treatment of HER-2 positive metastatic breast cancer
吡咯替尼联合白蛋白紫杉醇一线治疗HER2阳性转移性乳腺癌的疗效、安全性及转化研究
第一作者:李慧慧(山东省肿瘤医院)
 
PO4-05-04 Comparative effectiveness of Palbociclib plus Aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2-advanced breast cancer in Chinese clinical practice:a realworld study
哌柏西利联合芳香酶抑制剂对比单药氟维司群作为HR+/HER2-晚期乳腺癌初始内分泌治疗在中国临床实践中的比较效果:一项真实世界的研究
第一作者:Jian Yue(中国医学科学院肿瘤医院)
 
PO4-05-08 Primary endocrine therapy resistance in patients with de novo HR+/HER2-metastatic breast Cancer:a National Cancer Information Database Analysis in China
新发HR+/HER2-转移性乳腺癌患者的原发性内分泌治疗耐药:中国国家癌症信息数据库分析
第一作者:陈占红(浙江省肿瘤医院)
 
PO4-05-10 A Carryover Effect:Antibody Drug Conjugates Constantly Provide a Substantial Improvement in Overall Survival more than in Progression-free Survival
结转效应:抗体药物偶联物不断提供的总体生存期实质性改善比无进展生存期多
第一作者:I-Chun Chen(台湾大学肿瘤医院)
 
PO4-07-04 Breast Cancer HER2 Status Prediction from Hematoxylin-Eosin Stained Images Using Point Cloud Transformer
用点云变压器预测苏木精-伊红染色图像的乳腺癌HER2状态
第一作者:Bao Li(中国科学院自动化研究所)
 
PO4-08-01 Methylsterol monooxygenase 1(MSMO1)modulates endoplasmic reticulum stress through cholesterol metabolic reprogramming to alter chemotherapy sensitivity in breast cancer
甲基甾醇单加氧酶1(MSMO1)通过胆固醇代谢重编程调节内质网应激,改变乳腺癌化疗敏感性
第一作者:Hengyu Ren(复旦大学附属肿瘤医院)
 
PO4-10-07 Understanding Psychological distress in patients prior to breast cancer diagnosis:Mixed Methods Study
了解乳腺癌诊断前患者的心理困扰:混合方法研究
第一作者:Yan Gao(山西白求恩医院)
 
PO4-10-08 Building a standard methodology:Early Gynecologic Consultation and Bone Mass Density Examination in Breast Cancer Patients Receiving Endocrine Therapy
标准方法学的建立:接受内分泌治疗的乳腺癌患者早期妇科会诊和骨密度检查
第一作者:Chiu Ching-Wen(台北医科大学)
 
PO4-13-09 Paclitaxel affects the efficacy of PD-1 blockade by interfering with lipid metabolism reprogramming in patients with breast cancer
紫杉醇通过干扰乳腺癌患者脂质代谢重编程影响PD-1阻断的疗效
第一作者:莫红楠(中国医学科学院肿瘤医院)
 
PO4-16-05 Identification of functional HLA-A*11:01-restricted driver gene PIK3CA mutation specific Tcell receptors
功能性HLA-A*11:01-限制性驱动基因PIK3CA突变特异性T细胞受体的鉴定
第一作者:Meiying shen(重庆医科大学第一附属医院)
 
PO4-18-03 Combined Treatment with Pyrotinib and Chrysin Synergistically Improve the Autophagy Level in HER2-Positive Breast Cancer by Regulating the miR-16-5p/ZBTB16/G6PD Axis.
吡咯替尼联合白杨素通过调节miR-16-5p/ZBTB16/G6PD轴协同提升HER2阳性乳腺癌的自噬水平
第一作者:罗婷(四川大学华西医院)
 
PO4-18-04 An exploratory study of Trastuzumab Deruxtecan neoadjuvant therapy in HER2-positive or HER2-low early or locally advanced breast cancer after a poor response to neoadjuvant chemotherapy
对新辅助化疗反应不佳的HER2阳性或HER2低表达的早期或局部晚期乳腺癌进行T-DXd新辅助治疗的探索性研究
第一作者:张瑾(天津医科大学肿瘤医院)
 
PO4-20-02 A prospective,randomized,controlled clinical trial comparing different PEG-rhG-CSF administration times to treat chemotherapy-induced neutropenia and febrile neutropenia in early breast cancer
一项前瞻性、随机、对照临床试验,比较不同PEG-rhG-CSF给药时间治疗化疗诱导的早期乳腺癌中性粒细胞减少症和发热性中性粒细胞减少症
第一作者:查小明(南京医科大学第一附属医院)
 
PO4-22-11 Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Twostage IBBR Augmented With TiLoop®Bra(COSTA)
即刻一期IBBR与TiLoop®Bra(COSTA)增强扩展-植入两期IBBR安全性的比较研究
第一作者:杨犇龙(复旦大学附属肿瘤医院)
 
PO4-23-04 Is breast-conserving surgery an optional local therapy for non-inflammatory skin involvement(T4b)breast cancer?A Propensity Score Matching and Inverse Probability Weighting Analysis of SEER Database Results
第一作者:Jingyi Lin(福建医科大学附属协和医院)
 
PO4-25-02 Long-range Deployment of Tumor-antigen Specific Cytotoxic T Lymphocytes Inhibits Lung Metastasis of Breast Cancer
肿瘤抗原特异性细胞毒性T淋巴细胞的远程部署抑制乳腺癌肺转移
第一作者:Yue Xing(中山大学孙逸仙纪念医院)
 
PO4-27-05 A phase I open-label dose escalation trial of FWD1802 as monotherapy and in combination with palbociclib in patients with ER+/HER2-unresectable locally advanced or metastatic breast cancer with or without ESR1 mutations
在伴有或不伴有ESR1突变的ER+/HER2-不可切除的局部晚期或转移性乳腺癌患者中,FWD1802作为单药和联合哌柏西利的Ⅰ期开放标签剂量递增试验
第一作者:Ling Zeng(深圳市福恩药业有限公司)
 
PO4-28-07 SLC26A9 promotes triple-negative breast cancer progression by regulating lipid Metabolism
SLC26A9通过调节脂质代谢促进三阴性乳腺癌进展
第一作者:Yingming Zhou(遵义医科大学附属医院)
 
专场:POSTER SESSION 5
时间:12月8日12:00 pm-2:00 pm
地点:Halls 2-3
 
PO5-01-04 HER2 Amplification Level and Focal/Broad Region Size as Predictors of Treatment Response in Neoadjuvant Chemotherapy and Anti-HER2 Therapy for HER2-Positive Breast Cancer
HER2扩增水平和局灶/广域大小作为HER2阳性乳腺癌新辅助化疗和抗HER2治疗反应的预测因子
第一作者:廖宁(广东省人民医院)
 
PO5-02-08 Prognostic value of serum lipid levels in breast cancer patients who received neoadjuvant chemotherapy:A retrospective exploratory analysis of the prospective cohort
接受新辅助化疗的乳腺癌患者血脂水平的预后价值:前瞻性队列的回顾性探索性分析:接受新辅助化疗的乳腺癌患者血脂水平的预后价值
第一作者:Xinru Chen(上海交通大学医学院仁济医院)
 
PO5-02-10 Favorable effect of HER2-low expression on prognosis for breast cancers after neoadjuvant chemotherapy
her2低表达对乳腺癌新辅助化疗后预后的有利影响
第一作者:Yingying Zhao(上海交通大学医学院仁济医院)
 
PO5-03-05 Rethinking the value of pathologic complete response rate for the survival outcomes of early triple-negative breast cancer treated with neoadjuvant chemotherapy:a systematic review and network meta-analysis
重新思考病理完全缓解率对早期三阴性乳腺癌新辅助化疗生存结局的价值:系统回顾和网络荟萃分析
第一作者:Xiaoying Qiao(北京大学人民医院)
 
PO5-04-01 Inetetamab combined with sirolimus and chemotherapy in HER2 positive metastatic breast cancer patients with abnormal activation of Pi3k/Akt/mTOR pathway after trastuzumab treatment
Inetetamab+sirolimus+化疗治疗曲妥珠单抗治疗后Pi3k/Akt/mTOR通路异常活化的HER2阳性转移性乳腺癌患者
第一作者:李俏(中国医学科学院肿瘤医院)
 
PO5-07-02 AI-assisted interpretation of PD-L1 CPS improves the precision medicine in Triple-negative breast cancer
AI辅助解读PD-L1 CPS提高了三阴性乳腺癌的精准治疗
第一作者:Jinze Li(河北医科大学第四医院)
 
PO5-07-05 Deep learning can diagnose axillary lymph node metastases on optical virtual histologic images in breast cancer patients during surgery
深度学习可以通过光学虚拟组织学图像诊断乳腺癌患者术中腋窝淋巴结转移
第一作者:Shuwei Zhang(北京大学人民医院)
 
PO5-18-09 Anthracycline-free neoadjuvant therapy with nab-paclitaxel and carboplatin in non-luminal breast cancer:a single-arm phase II trial
新辅助治疗去蒽环类联合白蛋白-紫杉醇和卡铂治疗非luminal型乳腺癌:单臂Ⅱ期试验
第一作者:Deyue Liu(上海市第一人民医院)
 
PO5-21-05 An Endocrine Resistant-Related Gene Signature Revealing the Tumor Microenvironment to Predict the Prognosis of Hormone Receptor-Positive Breast Cancer Patients
揭示肿瘤微环境的内分泌抵抗相关基因特征预测激素受体阳性乳腺癌患者的预后
第一作者:Xiyu Kang(中国医学科学院肿瘤医院)
 
PO5-24-10 Clinical significance and immune landscape analyses of the immune related genes based prognostic signature for HER2 positive breast cancer
基于HER2阳性乳腺癌预后特征的免疫相关基因的临床意义和免疫景观分析
第一作者:Xiaofen Li(福建省肿瘤医院)
 
往期推荐

 

版面编辑:张靖璇  责任编辑:无医学编辑

本内容仅供医学专业人士参考


SABCS

分享到: 更多

相关幻灯